脑转移患者-话题@MedSci

#脑转移患者#

17篇内容 | 276人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2186668, encodeId=9626218666869, content=<a href='/topic/show?id=8f5c82594d5' target=_blank style='color:#2F92EE;'>#肾癌#</a> <a href='/topic/show?id=56b0194220e' target=_blank style='color:#2F92EE;'>#一线治疗#</a> <a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=Eur. Urol：接受一线治疗的肾细胞癌脑转移患者的结果：国际转移性肾细胞癌数据库联盟的结果, objectType=article, longId=812841, objectId=f0798128411e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240208/1707406953133_6145188.jpg, objectUrl=/article/show_article.do?id=f0798128411e, replyNumber=0, likeNumber=0, createdTime=2024-02-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=f0798128411e, moduleTitle=Eur. Urol：接受一线治疗的肾细胞癌脑转移患者的结果：国际转移性肾细胞癌数据库联盟的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0798128411e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1810487, encodeId=45d5181048e8b, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, objectType=article, longId=727788, objectId=2cfae27788c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cfae27788c8, replyNumber=0, likeNumber=33, createdTime=2023-02-15, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cfae27788c8, moduleTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cfae27788c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810486, encodeId=a2551810486b9, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）, objectType=article, longId=723571, objectId=265ee235713c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265ee235713c, replyNumber=0, likeNumber=42, createdTime=2022-08-18, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265ee235713c, moduleTitle=Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=265ee235713c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810484, encodeId=12d91810484af, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效, objectType=article, longId=217179, objectId=edee21e17926, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edee21e17926, replyNumber=0, likeNumber=39, createdTime=2022-07-27, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edee21e17926, moduleTitle=J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edee21e17926)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810485, encodeId=bb87181048567, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况, objectType=article, longId=220855, objectId=b2bf220855c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2bf220855c8, replyNumber=0, likeNumber=42, createdTime=2022-04-09, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2bf220855c8, moduleTitle=Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2bf220855c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810483, encodeId=73f91810483e9, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , objectType=article, longId=217043, objectId=644421e04318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644421e04318, replyNumber=0, likeNumber=27, createdTime=2022-05-30, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644421e04318, moduleTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=644421e04318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810482, encodeId=6db518104825a, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=Neurology：肿瘤脑转移患者，可考虑使用当癫痫药物降低癫痫发作风险, objectType=article, longId=205828, objectId=8cf52058289a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cf52058289a, replyNumber=0, likeNumber=51, createdTime=2021-05-19, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cf52058289a, moduleTitle=Neurology：肿瘤脑转移患者，可考虑使用当癫痫药物降低癫痫发作风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cf52058289a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810481, encodeId=7d83181048170, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=美例秀秀｜HER2阳性乳腺癌伴脑转移患者治疗, objectType=article, longId=153321, objectId=26d1153321b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26d1153321b9, replyNumber=0, likeNumber=36, createdTime=2019-04-12, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d1153321b9, moduleTitle=美例秀秀｜HER2阳性乳腺癌伴脑转移患者治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26d1153321b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810480, encodeId=4cfd1810480c3, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切, objectType=article, longId=150187, objectId=c14115018eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c14115018eac, replyNumber=0, likeNumber=37, createdTime=2018-11-01, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c14115018eac, moduleTitle=【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c14115018eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810478, encodeId=69c518104e84d, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=Lancet：推荐将nivolumab联合伊匹单抗作为无症状未治疗过的黑色素瘤脑转移患者的一线疗法, objectType=article, longId=133714, objectId=5089133e14b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5089133e14b6, replyNumber=0, likeNumber=39, createdTime=2018-07-07, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5089133e14b6, moduleTitle=Lancet：推荐将nivolumab联合伊匹单抗作为无症状未治疗过的黑色素瘤脑转移患者的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5089133e14b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810479, encodeId=d64618104e9c1, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=Sci Rep：癌抗原-125对肺腺癌伴脑转移患者的预后价值, objectType=article, longId=134478, objectId=c07f1344e865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c07f1344e865, replyNumber=0, likeNumber=38, createdTime=2018-05-27, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c07f1344e865, moduleTitle=Sci Rep：癌抗原-125对肺腺癌伴脑转移患者的预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c07f1344e865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810477, encodeId=e7f218104e783, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险, objectType=article, longId=120687, objectId=615212068e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=615212068e26, replyNumber=0, likeNumber=34, createdTime=2018-05-06, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=615212068e26, moduleTitle=【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=615212068e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810476, encodeId=c62b18104e60c, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=ASCO:肺癌患者无进展生存期新药显著延长脑转移患者无进展生存期, objectType=article, longId=100969, objectId=8290100969be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8290100969be, replyNumber=0, likeNumber=38, createdTime=2017-07-09, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8290100969be, moduleTitle=ASCO:肺癌患者无进展生存期新药显著延长脑转移患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8290100969be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810474, encodeId=f1f118104e4a4, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=JCO：EGFR突变型NSCLC脑转移患者的治疗策略, objectType=article, longId=99333, objectId=ac4999333a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac4999333a5, replyNumber=0, likeNumber=36, createdTime=2017-10-01, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac4999333a5, moduleTitle=JCO：EGFR突变型NSCLC脑转移患者的治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac4999333a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810475, encodeId=b7c018104e556, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=ASCO2017：肿瘤脑转移患者生存期影响因素, objectType=article, longId=100769, objectId=0909100e69fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0909100e69fb, replyNumber=0, likeNumber=33, createdTime=2018-04-24, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0909100e69fb, moduleTitle=ASCO2017：肿瘤脑转移患者生存期影响因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0909100e69fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810473, encodeId=134718104e34f, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=Lancet：对于非小细胞肺癌脑转移患者来说，全脑放疗收效甚微（QUARTZ）, objectType=article, longId=76703, objectId=e95be67032a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95be67032a, replyNumber=0, likeNumber=36, createdTime=2016-12-01, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95be67032a, moduleTitle=Lancet：对于非小细胞肺癌脑转移患者来说，全脑放疗收效甚微（QUARTZ）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e95be67032a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810471, encodeId=382918104e1e3, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=Lancet :黑色素瘤脑转移患者可从依匹单抗中受益, objectType=article, longId=4424, objectId=59444424e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59444424e1, replyNumber=0, likeNumber=35, createdTime=2012-06-12, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59444424e1, moduleTitle=Lancet :黑色素瘤脑转移患者可从依匹单抗中受益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59444424e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1810472, encodeId=1da918104e212, content=<a href='/topic/show?id=e3258513293' target=_blank style='color:#2F92EE;'>#脑转移患者#</a>, objectTitle=BMC Cancer:拉帕替尼+卡培他滨对某些乳腺癌伴或不伴脑转移患者疗效相同, objectType=article, longId=8453, objectId=937c84530c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=937c84530c, replyNumber=0, likeNumber=33, createdTime=2013-02-24, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=937c84530c, moduleTitle=BMC Cancer:拉帕替尼+卡培他滨对某些乳腺癌伴或不伴脑转移患者疗效相同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=937c84530c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

脑转移患者

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肾癌# #一线治疗# #脑转移患者#

Eur. Urol：接受一线治疗的肾细胞癌脑转移患者的结果：国际转移性肾细胞癌数据库联盟的结果

2024-02-09发表于陕西省

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS

2023-02-15

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）

2022-08-18

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效

2022-07-27

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

Front Oncol：回顾性分析实体恶性肿瘤伴有脑转移患者从免疫检查点抑制剂治疗的获益情况

2022-04-09

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效

2022-05-30

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

Neurology：肿瘤脑转移患者，可考虑使用当癫痫药物降低癫痫发作风险

2021-05-19

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

美例秀秀｜HER2阳性乳腺癌伴脑转移患者治疗

2019-04-12

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切

2018-11-01

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

Lancet：推荐将nivolumab联合伊匹单抗作为无症状未治疗过的黑色素瘤脑转移患者的一线疗法

2018-07-07

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

Sci Rep：癌抗原-125对肺腺癌伴脑转移患者的预后价值

2018-05-27

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

【ESMO Asia】FLAURA研究：奥希替尼显著降低脑转移患者进展和死亡风险

2018-05-06

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

ASCO:肺癌患者无进展生存期新药显著延长脑转移患者无进展生存期

2017-07-09

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

JCO：EGFR突变型NSCLC脑转移患者的治疗策略

2017-10-01

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

ASCO2017：肿瘤脑转移患者生存期影响因素

2018-04-24

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

Lancet：对于非小细胞肺癌脑转移患者来说，全脑放疗收效甚微（QUARTZ）

2016-12-01

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

Lancet :黑色素瘤脑转移患者可从依匹单抗中受益

2012-06-12

智慧医人 (审核中...)

前往app查看评论内容

#脑转移患者#

BMC Cancer:拉帕替尼+卡培他滨对某些乳腺癌伴或不伴脑转移患者疗效相同

2013-02-24

科室
- - 订阅+
  - 更多科室
工具
服务